Clinical Trial Update: Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• 23-valent pneumococcal polysaccharide vaccine (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: Sinovac Biotech Co., Ltd | Conditions: Pneumococcal Infections | Phase 4 | Status: COMPLETED